The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Subscribe To Our Newsletter & Stay Updated